Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

RPGR is the most common target for gene therapies in pipeline development for retinitis pigmentosa

Gene therapies dominate the pipeline landscape for retinitis pigmentosa (RP) with the gene coding for retinitis pigmentosa GTPase regulator (RPGR) the most common target among these therapies for retinitis pigmentosa (RP), according to the latest research by GlobalData, a leading data and analytics company. Vinie Varkey, Senior Ophthalmology Analyst at GlobalData, comments: “RP is a […]
Read more

Government reimbursement for dialysis patients on AstraZeneca/FibroGen’s roxadustat faces fiscal challenges, says GlobalData

Reimbursement for dialysis patients on AstraZeneca’s/FibroGen’s roxadustat needs to be untangled such that it can be billed separately and be accompanied by hikes in eventual payment bundles, as reported by Manasi Vaidya, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Vaidya comments: “Clarity on how the US Centers […]
Read more

Gilead, AstraZeneca and Pfizer likely to emerge as winners of COVID-19 therapeutics and vaccine development race, says GlobalData

More than 1,200 therapeutics and vaccines have entered the research and development (R&D) pipeline since January 2020, according to GlobalData, a leading data and analytics company, and that number grows every week. According to GlobalData’s Clinical and Commercial Analyzer tool, which rates the most promising and high-profile assets on a range of clinical and commercial […]
Read more

Market for graft versus host disease across five APAC markets to grow at 8.2% CAGR over next 10 years, says GlobalData

The market for graft versus host disease (GvHD) prophylaxis and treatment in the five growth markets (5GM*) in the Asia-Pacific (APAC) region will undergo steady growth at a compound annual growth rate (CAGR) of 8.2% from 2018 to 2028, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Graft Versus Host Disease […]
Read more

COVID-19 vaccines require innovative approaches to achieve best balance of safety and efficacy

At present, more than 200 prophylactic vaccines are in development for COVID-19. While promising candidates should be selected for diversity, the novel nature of SARS-CoV-2 requires innovative approaches to achieve the best balance of safety and efficacy, says GlobalData, a leading data and analytics company. Mohamed Abukar, MSc, Clinical Trials Analyst at GlobalData, comments: “AstraZeneca’s AZD-1222 […]
Read more

Biotech IPO deals not slowing during COVID-19

Biotech company initial public offering (IPO) valuations have shown resilience during the COVID-19 pandemic, compared to other industries. This is largely due to the unique nature of pharmaceuticals and the industry’s role in developing a COVID-19 drug, as well as drugs for other serious medical needs, says GlobalData, a leading data and analytics company. Sharon […]
Read more

Oncology remains market-leading therapy area with $142bn sales in 2019

In a global prescription drug market worth over $600bn, oncology has become the dominant area, claiming a market share of 23.4% as of 2019, followed by immunology at 12.4% and metabolic disorders at 10.8% according to GlobalData, a leading data and analytics company. GlobalData’s analysis of a proprietary dataset shows that global drug sales with […]
Read more

Trilaciclib’s regulatory advancement signals a significant moment for supportive cancer care, says GlobalData

Trilaciclib’s new drug application (NDA) acceptance signals a significant moment for cancer patients that need support with chemotherapy-induced toxicities – further highlighted by the fact that the therapy has been granted Breakthrough Therapy Designation by the US FDA. By being able to preserve bone marrow and immune system function, Trilaciclib’s mechanism of action (MoA) of […]
Read more
1 … 82 83 84 85 86 … 110